UroAlert - GU Oncology Weekly

April 16, 2026

Videos

Peer-to-Peer Clinical Conversations

Diagnostic Imaging and Treatment Options for Small Renal Masses - Fernando Pablo Secin

Fernando Secin

Zachary Klaassen hosts Fernando Secin to discuss the management of small renal masses.

ZUSDURI™ FDA Approved for Low-Grade Intermediate-Risk Bladder Cancer - Mark Schoenberg

Mark Schoenberg

Ashish Kamat speaks with Mark Schoenberg about the FDA approval of UGN-102 (ZUSDURI™), a reverse thermal gel containing mitomycin for intermediate-risk, low-grade non-muscle invasive bladder cancer.

Beyond the Abstracts

The Impact of Intravesical Instillations on Quality of Life in Patients with Non-Muscle-Invasive Bladder Cancer: A Systematic Review - Beyond the Abstract

Urine Glycosaminoglycan Scores for Surveillance of Recurrence in Intermediate- and High-risk Nonmetastatic Clear Cell Renal Cell Carcinoma-An Observational Prospective Multicentre Diagnostic Test Cohort Study - Beyond the Abstract

Conference Coverage

SES AUA 2026: Durable 24-Month Outcomes from BOND-003 Cohort C: Phase 3 Study of Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-unresponsive Non Muscle Invasive Bladder Cancer with CIS

EAU 2026: Real-World Efficacy of Avelumab Maintenance Therapy in Advanced Urothelial Carcinoma: Survival Impact of Early Transition After 2–3 Cycles of Chemotherapy

EAU 2026: Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced UTUC: CURATE-UTUC – A Multicenter Prospective Longitudinal Cohort Study

ASCO GU 2026: First Results from CORE-008 Cohort A: Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec in Patients with HR BCG-Naïve NMIBC

ASTRO Radiopharmaceutical Symposium 2026: Why Now is the Time to Build a Radiopharmaceutical Therapy Practice

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Serum Biomarkers in Bladder Cancer: NMR Metabolomics for Identification and Monitoring during Platinum-Based Therapy.

Real-World Treatment Sequences and Overall Survival in Metastatic Bladder Cancer: The STATES-Bladder Study - Beyond the Abstract

Clinical and genomic profiling of early-onset bladder cancer identifies key alterations and therapeutic targets.

Comorbidity alterations between time for diagnosis and radical cystectomy in patients with muscle invasive bladder cancer undergoing neoadjuvant chemotherapy.

Prospective Multicenter Study of ctDNA Versus Tumor Tissue Guiding FGFR-Targeted Therapy in Metastatic Urothelial Cancer - Beyond the Abstract

Large multicenter validation of urine RNA profile for urothelial carcinoma detection and surveillance.

A Long Noncoding RNA-based Classifier for Identifying More Aggressive Low-grade Ta Bladder Cancer with Elevated FGFR3 Activity - Beyond the Abstract

Sarcomatoid urothelial carcinoma with constitutive PD-L1 overexpression.

The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guérin.

Evaluating BCG response in primary and metachronous non-muscle invasive bladder cancer following prior upper tract urothelial cancer: A systematic review and meta-analysis.

Radiation and Avelumab in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer.

Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer - Beyond the Abstract

Perioperative outcomes following open radical cystectomy in the setting of locally advanced bladder cancer.

Real-world comparison of avelumab maintenance versus pembrolizumab at progression after first-line platinum-based chemotherapy in metastatic urothelial cancer.

Penile & Urethral Cancers

Fungating Mass of the Glans Penis: A Case Report and Discussion on Penile Squamous Cell Carcinoma.

Predicting inguinal lymph node metastasis in penile squamous cell carcinoma, from imaging, molecular biomarkers to multimodal AI: a narrative review.

Years of life lost in squamous cell carcinoma of the penis.

Prognostic value of the tumor immune microenvironment, PD-L1 and p16INK4A in penile squamous cell carcinoma.

Renal Cancer

Real-World Effectiveness and Safety of Pembrolizumab-Lenvatinib Versus Axitinib-Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Study.

Hepatic-Differentiated Subpopulation in Clear Cell Renal Cell Carcinoma: A Multi-Omics Analysis of Tumors With Lymphovascular Invasion.

Cachexia index as a prognostic indicator in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab: multicenter analysis.

Hospital variation in the treatment of cT1a renal cancer.

Oligoprogressive renal cell carcinoma: What is the role of surgery?

Real-World Evidence on Preoperative Targeted Therapy for Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus.

Pattern of Disease Recurrence and Outcomes after Progression of High-Risk Renal Cell Carcinoma (RCC) Patients Treated with Adjuvant Immunotherapy - Beyond the Abstract

sPaRT2 - Minimally Invasive Partial versus Radical Nephrectomy for cT2 Renal Cell Carcinoma: A National Matched-Pair Analysis (UroCCR 235).

Oncologic Outcomes of Microwave Ablation of Biopsy-Proven cT1a Renal Cell Carcinomas.

Belzutifan Efficacy in Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma Versus Natural History Control Arm.

Benmelstobart Plus Anlotinib Is Unlikely to Be Cost-Effective for Advanced Renal Cell Carcinoma: An Integrated Disease Burden and Cost-Effectiveness Analysis.

Safety, Feasibility and Prognostic Analysis of Surgical Treatment for High-Complexity Renal Tumours (RENAL Score ≥ 10): A Summary of Experience With Robotic Technology Applications.

Prostate Cancer

Real-World Effectiveness and Treatment Persistence of Darolutamide, Apalutamide, and Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Study.

Survival of Individuals Diagnosed With High-Risk, Regional, and Metastatic Prostate Cancer by Culturally and Linguistically Diverse Status: A Retrospective Cohort Study Set in Victoria, Australia.

Performance of an Artificial Intelligence Foundation Model for Prostate Radiotherapy Segmentation.

Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer.

Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET-CT in Characterising Bone Lesions in Prostate Cancer: A Single-Centre Study.

Harnessing Artificial Intelligence for Risk Stratification and Outcome Prediction in Urologic Cancers: A Systematic Review.

Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.

A Cost-Analysis and Micro-Costing Study of the Man Van Project: Comparing Prostate-Specific Antigen Testing Via a Nurse-Led Mobile Service with Primary Care - Beyond the Abstract

A Prolonged Nightly Fasting Plus Telehealth Coaching Intervention (PNF+) for Men on Androgen Deprivation Therapy for PCa: A Pilot Feasibility Randomized Controlled Trial.

ANGPTL3, Apo CIII, Leptin and Triglycerides Are Elevated in Metastatic Prostate Cancer.

Pathological Stage and Grade Determine the Impact of Focal Versus Extensive Positive Surgical Margins After Radical Prostatectomy.

Genomic Analysis of Puerto Rican Hispanic/Latino Men with Prostate Cancer.

Urine-Based Machine Learning Assay Detects Prostate Cancer.

Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial.

Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial.

Development of a Prognostic Prediction Model for Clinically Significant Prostate Cancer Based on Lesion Zone and Apparent Diffusion Coefficient Value Quantification - Beyond the Abstract

Cost-effectiveness of an artificial intelligence predictive model for guiding androgen deprivation therapy in intermediate-risk prostate cancer.

OncoEducate: A Pilot Study of Generative AI to Enhance Patient-Clinician Communication in Genitourinary Cancer Care.

Extended Follow-up from the Stereotactic Body Radiotherapy for High-risk Localized Carcinoma of the Prostate (SHARP) Consortium: Updated Analysis of 440 Patients.

Integrating Genomic Prostate Score with Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores to Predict Biochemical Recurrence after Radical Prostatectomy.

Hypo fractionated Versus Conventional IMRT in Unfavorable Intermediate- and High-Risk Prostate Cancer: A Phase II Comparative Study of PSA Kinetics, Dosimetric and Toxicity Outcomes.

Genome-wide methylome profiling of cell-free DNA enables prognostication of patients with castration-resistant prostate cancer.

Identifying preferences for prostate cancer screening among American Indian men (Project AIMEPCCo): Protocol for a discrete choice experiment.

Evaluating an AI-driven Triaging Workflow for MRI-based Clinically Significant Prostate Cancer Diagnosis: A Simulation Study.

Integrative molecular analyses of lineage identity and morphology in aggressive variant prostate cancer.

Evaluating MRI findings and biopsy strategies to maximize detection of grade progression in men on active surveillance for prostate cancer.

CREB5 regulates stem cell-like transcriptional programs to enhance tumor progression in prostate cancer.

Changing trends in androgen deprivation therapy prescribing for prostate cancer in England, 2015-2024.

The Proposed Introduction of a Prostate Cancer Screening Program in Germany: Procedure, Necessary Studies before Implementation, Benefits, and Risks.

Novel Theranostic Targets for Prostate Cancer Beyond Prostate-Specific Membrane Antigen.

Castration Resistance Accelerates Prostate Cancer Kinetics.

Genomic Prostate Score (GPS) as a Prognostic Biomarker in Patients With Localized Prostate Cancer Undergoing Focal Therapy.

Stereotactic Body Radiation Therapy (SBRT)-Induced 68Ga-PSMA PET Bone Flare.

Upper Tract Tumors

Histological Evaluation of Tertiary Lymphoid Structures Predicts Prognosis in Upper Tract Urothelial Carcinoma: A Cox-Based Nomogram Analysis.

Testicular Cancer

Genome-Wide Copy-Number Landscape of Germ Cell Tumors With Synchronous Conventional and "Somatic-Type" Malignancy Components.

Intranuclear Peripheral Overexpression of Pituitary-Tumor-Transforming Gene 1: Immunohistochemical Biomarker of Lymph Node Involvement in Testicular Seminoma.

Complications and clinical outcomes of retroperitoneal lymph node dissection for testicular cancer in a centralized population-based cohort in Sweden: insights from SWENOTECA.

Mental Health Burden of a Testicular Cancer Diagnosis: Insights from a Large Claims Database - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC